Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

NCT01882387 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Change in drug product development strategy

Conditions

Interventions

Sponsor

Tarix Pharmaceuticals